Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/karger/platelet-derived-mitogenic-activity-and-bone-marrow-fibrosis-in-RxR47sy0dx
References
References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.
- Publisher
- Karger
- Copyright
- © 1990 S. Karger AG, Basel
- ISSN
- 1424-8832
- eISSN
- 1424-8840
- DOI
- 10.1159/000216123
- Publisher site
- See Article on Publisher Site
Abstract
Mitogenic activity, measured as <sup>3</sup>H-thymidine incorporation by NIH 3T3 cells, following stimulation with platelet-rich-plasma-derived serum (PRS), platelet-poor-plasma-derived serum and platelet extract was studied in 14 patients with myeloproliferative disorders (MPD) and 7 normal subjects. Reduced mitogenic activity was found in PRS and platelet extract of patients with MPD, as compared to controls. The average levels of platelet-derived growth factor (PDGF) equivalents were as follows: 16.3 ± 7.2 pg/l06 platelets in controls, 6.2 ± 2.2 pg/l06 (p < 0.05) platelets in patients with polycythaemia vera, 1.8 ± 0.4 pg/10<sup>6</sup> (p < 0.01) platelets in patients with idiopathic myelofibrosis and 4.0 ± 0.8 pg/l06 (p < 0.05) platelets in patients with essential thrombocythaemia (Dunnett test). A reduction of intraplatelet levels of β-thromboglobulin, although not statistically significant, was found in the same patients. No apparent relation was found between the amount of PDGF equivalents and the degree of bone marrow fibrosis.
Journal
Pathophysiology of Haemostasis and Thrombosis – Karger
Published: Jan 1, 1990
Keywords: Myeloproliferative disorders; Platelet-derived growth factor; Myelofibrosis